<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02591836</url>
  </required_header>
  <id_info>
    <org_study_id>A4141001</org_study_id>
    <nct_id>NCT02591836</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients as Monotherapy or in Combination With Atorvastatin</brief_title>
  <official_title>An 8‐Week, Double‐Blind, Randomized, Placebo‐Controlled, Dose‐Ranging Study of the Efficacy and Safety of Gemcabene Administered as Monotherapy or in Combination With Atorvastatin in the Treatment of Hypercholesterolemic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gemphire Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gemphire Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this placebo-controlled study is to evaluate the low‐density
      lipoprotein cholesterol (LDL‐C) efficacy and dose‐response of gemcabene 300, 600 and 900
      mg/day administered as monotherapy or in combination with atorvastatin 10, 40, and 80 mg/day
      to hypercholesterolemic patients.

      Secondary purposes include evaluating the effects of high‐sensitivity C-reactive protein
      (hsCRP), high‐density lipoprotein cholesterol (HDL‐C), triglycerides (TG) and apolipoprotein
      B (ApoB), and safety and efficacy of gemcabene monotherapy and gemcabene/atorvastatin
      combination.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">June 2003</completion_date>
  <primary_completion_date type="Actual">June 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL‐C percent change from baseline</measure>
    <time_frame>56 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HDL-C percent change from baseline</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TG percent change from baseline</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein-B percent change from baseline</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory</measure>
    <time_frame>56 days</time_frame>
    <description>Clinical Laboratory Abnormalities</description>
  </secondary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Actual">277</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Gemcabene 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcabene 300 mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcabene 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcabene 600 mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcabene 900 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcabene 900 mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 80 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcabene 300 mg &amp; Atorvastatin 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcabene 300 mg &amp; Atorvastatin 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcabene 300 mg &amp; Atorvastatin 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcabene 600 mg &amp; Atorvastatin 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcabene 600 mg &amp; Atorvastatin 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcabene 600 mg &amp; Atorvastatin 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcabene 900 mg &amp; Atorvastatin 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcabene 900 mg &amp; Atorvastatin 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcabene 900 mg &amp; Atorvastatin 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcabene</intervention_name>
    <description>Gemcabene</description>
    <arm_group_label>Gemcabene 300 mg</arm_group_label>
    <arm_group_label>Gemcabene 600 mg</arm_group_label>
    <arm_group_label>Gemcabene 900 mg</arm_group_label>
    <arm_group_label>Gemcabene 300 mg &amp; Atorvastatin 10 mg</arm_group_label>
    <arm_group_label>Gemcabene 300 mg &amp; Atorvastatin 40 mg</arm_group_label>
    <arm_group_label>Gemcabene 300 mg &amp; Atorvastatin 80 mg</arm_group_label>
    <arm_group_label>Gemcabene 600 mg &amp; Atorvastatin 10 mg</arm_group_label>
    <arm_group_label>Gemcabene 600 mg &amp; Atorvastatin 40 mg</arm_group_label>
    <arm_group_label>Gemcabene 600 mg &amp; Atorvastatin 80 mg</arm_group_label>
    <arm_group_label>Gemcabene 900 mg &amp; Atorvastatin 10 mg</arm_group_label>
    <arm_group_label>Gemcabene 900 mg &amp; Atorvastatin 40 mg</arm_group_label>
    <arm_group_label>Gemcabene 900 mg &amp; Atorvastatin 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin</description>
    <arm_group_label>Atorvastatin 10 mg</arm_group_label>
    <arm_group_label>Atorvastatin 40 mg</arm_group_label>
    <arm_group_label>Atorvastatin 80 mg</arm_group_label>
    <arm_group_label>Gemcabene 300 mg &amp; Atorvastatin 10 mg</arm_group_label>
    <arm_group_label>Gemcabene 300 mg &amp; Atorvastatin 40 mg</arm_group_label>
    <arm_group_label>Gemcabene 300 mg &amp; Atorvastatin 80 mg</arm_group_label>
    <arm_group_label>Gemcabene 600 mg &amp; Atorvastatin 10 mg</arm_group_label>
    <arm_group_label>Gemcabene 600 mg &amp; Atorvastatin 40 mg</arm_group_label>
    <arm_group_label>Gemcabene 600 mg &amp; Atorvastatin 80 mg</arm_group_label>
    <arm_group_label>Gemcabene 900 mg &amp; Atorvastatin 10 mg</arm_group_label>
    <arm_group_label>Gemcabene 900 mg &amp; Atorvastatin 40 mg</arm_group_label>
    <arm_group_label>Gemcabene 900 mg &amp; Atorvastatin 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and Females

          -  18‐70 years old

          -  Received a statin as monotherapy while having a LDL‐C &gt;100 mg d/L at initial clinical
             washout visit OR

          -  Received no lipid‐altering drugs since the initial clinic washout visit and had a mean
             LDL‐C as follows at 2 qualifying visits:

               -  ≥ 130 mg/dL if National Cholesterol Education Program (NCEP) Adult Treatment
                  Panel III (ATP III) Coronary Heard Disease (CHD) risk ≥ 10%; OR

               -  ≥ 160 mg/dL if NCEP ATP III CHD risk &lt; 10%

          -  Had variability of 2 qualifying LDL‐C &lt;20% (i.e. lowest value/highest value &gt;0.8). An
             additional qualifying visit may have been completed by patients who were washing off
             lipid medication in order to reassess LDL‐C variability; and

          -  Had a mean LDL‐C &lt; 250 mg/dL at 2 qualifying visits

        Exclusion Criteria:

          -  Women of childbearing potential, pregnant or lactating;

          -  Body Mass Index (BMI) &gt;38kg/m²;

          -  TG &gt;400 mg/dL at Visit B2 or B3

          -  Unexplained creatinine phosphokinase (CPK) &gt; 3 x Upper Limit of Normal (ULN) or those
             with a history of unexplained myopathy (including rhabdomyolysis);

          -  Documented cardiac history of: Myocardial infarction*, severe or unstable angina
             pectoris, coronary angioplasty, coronary artery bypass graft, symptomatic carotid
             artery disease or peripheral artery disease, ventricular arrhythmias, recurrent
             supraventricular tachycardia, abnormal QTC interval (QT corrected &gt; 0.44 sec), heart
             failure or any other major cardiovascular event resulting in hospitalization

          -  Uncontrolled hypertension*

          -  Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus (HbA1c &gt;8%) or any
             diabetic patient who takes insulin and/or thiazolidinediones

          -  Renal dysfunction including chronic renal failure or insufficiency, or creatinine &gt;2.0
             mg/dL;

          -  Hepatic dysfunction

          -  Uncontrolled hypothyroidism

          -  Abnormal urinalysis

          -  Currently taking any of the following medications:

               -  Potent CYP3A4 inhibitors including indinavir, nelfinavir, ritonavir, saquinavir,
                  amiodarone, cimetidine, clarithromycin, erythromycin, erythromycin, fluoxetine,
                  itraconazole, ketoconazole, nefazodone and troleandomycin as well as grapefruit
                  juice;

               -  Thiazolidinediones (Avandia, Actos);

               -  Immunosuppressive agents;

               -  St. John's wort

          -  Taking any of the following lipid‐altering medications within 5 weeks prior to
             randomization:

               -  Lipid‐regulating drugs: Niacin (crystalline &gt;500mg/day, slow release or time
                  release), psyllium preparation such as Metamucil (&gt;2 tablespoons/day), fibrates
                  and derivatives, bile cholesterol absorption inhibitors including ezetimibe;

               -  Any supplement containing plan sterols/stanols (i.e. Benecol, beta‐sitosterol,
                  Cholestatin, Phytoquest, Take Control) or cholestin (i.e. Chinese red yeast,
                  fermented on rice; Hong Qu, Hong Chu, Herbvalin, Ruby Monascus, Monascus
                  purpureus rice);

               -  Neomycin (oral);

               -  Adrenocortical steroids*

               -  Sibutramine (Meridia);

               -  Insulin;

               -  Orlistat (Xenical);

               -  Isotretinoin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2015</study_first_submitted>
  <study_first_submitted_qc>October 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2015</study_first_posted>
  <last_update_submitted>October 28, 2015</last_update_submitted>
  <last_update_submitted_qc>October 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LDL‐C</keyword>
  <keyword>Lipid Regulator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

